450 related articles for article (PubMed ID: 15217305)
1. The role of cost-effectiveness analysis in the era of pharmacogenomics.
Flowers CR; Veenstra D
Pharmacoeconomics; 2004; 22(8):481-93. PubMed ID: 15217305
[TBL] [Abstract][Full Text] [Related]
2. Assessing the cost-effectiveness of pharmacogenomics.
Veenstra DL; Higashi MK; Phillips KA
AAPS PharmSci; 2000; 2(3):E29. PubMed ID: 11741245
[TBL] [Abstract][Full Text] [Related]
3. Economic opportunities and challenges for pharmacogenomics.
Deverka PA; Vernon J; McLeod HL
Annu Rev Pharmacol Toxicol; 2010; 50():423-37. PubMed ID: 20055709
[TBL] [Abstract][Full Text] [Related]
4. Systematic review of pharmacoeconomic studies of pharmacogenomic tests.
Beaulieu M; de Denus S; Lachaine J
Pharmacogenomics; 2010 Nov; 11(11):1573-90. PubMed ID: 21121811
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics: bridging the gap between science and practice.
Lee KC; Ma JD; Kuo GM
J Am Pharm Assoc (2003); 2010; 50(1):e1-14; quiz e15-7. PubMed ID: 20368146
[TBL] [Abstract][Full Text] [Related]
6. A framework to evaluate the economic impact of pharmacogenomics.
Stallings SC; Huse D; Finkelstein SN; Crown WH; Witt WP; Maguire J; Hiller AJ; Sinskey AJ; Ginsburg GS
Pharmacogenomics; 2006 Sep; 7(6):853-62. PubMed ID: 16981846
[TBL] [Abstract][Full Text] [Related]
7. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics.
Phillips KA; Veenstra D; Van Bebber S; Sakowski J
Pharmacogenomics; 2003 May; 4(3):231-9. PubMed ID: 12718713
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice.
Manolopoulos VG
Clin Chem Lab Med; 2007; 45(7):801-14. PubMed ID: 17617019
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.
Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S
Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis in pharmacogenomics.
Payne K; Shabaruddin FH
Pharmacogenomics; 2010 May; 11(5):643-6. PubMed ID: 20415553
[TBL] [Abstract][Full Text] [Related]
11. Translating pharmacogenomics: challenges on the road to the clinic.
Swen JJ; Huizinga TW; Gelderblom H; de Vries EG; Assendelft WJ; Kirchheiner J; Guchelaar HJ
PLoS Med; 2007 Aug; 4(8):e209. PubMed ID: 17696640
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics: the promise of personalized medicine.
Mancinelli L; Cronin M; Sadée W
AAPS PharmSci; 2000; 2(1):E4. PubMed ID: 11741220
[TBL] [Abstract][Full Text] [Related]
13. Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality?
Vizirianakis IS
Pharmacogenomics; 2005 Oct; 6(7):701-11. PubMed ID: 16207147
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.
van den Akker-van Marle ME; Gurwitz D; Detmar SB; Enzing CM; Hopkins MM; Gutierrez de Mesa E; Ibarreta D
Pharmacogenomics; 2006 Jul; 7(5):783-92. PubMed ID: 16886902
[TBL] [Abstract][Full Text] [Related]
15. [Drug therapy and pharmacogenomics--hopes and facts].
Müller-Zellenberg U; Müller M
Wien Med Wochenschr; 2005 Feb; 155(3-4):45-9. PubMed ID: 15791775
[TBL] [Abstract][Full Text] [Related]
16. Payer perspectives on pharmacogenomics testing and drug development.
Epstein RS; Frueh FW; Geren D; Hummer D; McKibbin S; O'Connor S; Randhawa G; Zelman B
Pharmacogenomics; 2009 Jan; 10(1):149-51. PubMed ID: 19102724
[TBL] [Abstract][Full Text] [Related]
17. The challenges of implementing pharmacogenomic testing in the clinic.
Moyer AM; Caraballo PJ
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):567-577. PubMed ID: 28949250
[TBL] [Abstract][Full Text] [Related]
18. Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations.
Morley KI; Hall WD
J Mol Med (Berl); 2004 Jan; 82(1):21-30. PubMed ID: 14598045
[TBL] [Abstract][Full Text] [Related]
19. Does pharmacogenomics provide an ethical challenge to the utilisation of cost-effectiveness analysis by public health systems?
La Caze A
Pharmacoeconomics; 2005; 23(5):445-7. PubMed ID: 15896096
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level?
Bala MV; Zarkin GA
Pharmacoeconomics; 2004; 22(8):495-8. PubMed ID: 15217306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
